Research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Genelux in a report released on Monday, March 31st ...

Equities research analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Defiance Silver in a research ...

H.C. Wainwright sees increased uncertainty for Sarepta’s Elevidys franchise after the European Medicines Agency placed a clinical hold on three drug trials. The clinical hold on ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

H.C. Wainwright raised the firm’s price target on Compass Therapeutics (CMPX) to $24 from $10 and keeps a Buy rating on the shares. The company ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

Highlights,Vanda Pharmaceuticals posts improved earnings, surpassing market expectations.,Company executives increase stock ...

On Thursday, 27 March 2025, Nektar Therapeutics (NASDAQ: NKTR) participated in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The company provided a strategic ...

NEW YORK, April 01, 2025--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC ("HCW") announces a significant milestone, securing its #1 ranking for the 40th consecutive quarter in PlacementTracker’s ...